Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients
抗血管生成治疗的替代标志物和贝伐单抗联合放疗和化疗的剂量限制性毒性:直肠癌患者 I 期试验的持续经验
期刊:Journal of Clinical Oncology
影响因子:42.1
doi:10.1200/JCO.2005.02.5635
Christopher G Willett, Yves Boucher, Dan G Duda, Emmanuelle di Tomaso, Lance L Munn, Ricky T Tong, Sergey V Kozin, Lucine Petit, Rakesh K Jain, Daniel C Chung, Dushyant V Sahani, Sanjeeva P Kalva, Kenneth S Cohen, David T Scadden, Alan J Fischman, Jeffrey W Clark, David P Ryan, Andrew X Zhu, Lawrenc